Targeting Mutant AKT in Cancer.
The results of a phase I basket trial suggest that the AKT1 E17K mutation is a valid therapeutic target. AZD5363, an investigational pan-AKT inhibitor, may benefit patients with a range of solid tumors bearing this genetic alteration.